September 13th, 2013
Should We Treat Nonculprit Lesions During PCI for STEMI?
David S Wald, MA MD FRCP, Richard A. Lange, MD, MBA and L. David Hillis, MD
CardioExchange’s Rick Lange and David Hillis interview David Wald about his group’s recently published findings from the PRAMI trial of “preventive” PCI in STEMI patients. Based on results of previous nonrandomized, observational studies, stenting non-infarct coronary stenoses during primary PCI has been discouraged. The Preventive Angioplasty in Acute Myocardial Infarction (PRAMI) trial in 465 STEMI patients assessed whether […]
February 22nd, 2013
SYNTAX After 5 Years: Any Change in Results (or Your Practice)?
Richard A. Lange, MD, MBA and L. David Hillis, MD
The 5 year results of the SYNTAX (SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery) trial are now published. SYNTAX assessed the optimal revascularization strategy for patients with left main and/or 3-vessel disease by randomly assigning such patients to CABG or PCI (with a first-generation paclitaxel-eluting stent) and then determining the rate of […]
December 27th, 2012
Selections from Richard Lehman’s Literature Review: December 27th
Richard Lehman, BM, BCh, MRCGP
This week’s topics include an intensive lifestyle intervention and its association with type-2 diabetes remission, strategies for multivessel revascularization in patients with diabetes, and more.
NEJM Journal Watch — Recent Cardiology Articles- To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?
- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy